Lanjuan Li

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/10966016/publications.pdf

Version: 2024-02-01

102 papers	15,741 citations	44042 48 h-index	32815 100 g-index
103 all docs	103 docs citations	103 times ranked	23224 citing authors

#	Article	IF	Citations
1	The protective effects of a d-tetra-peptide hydrogel adjuvant vaccine against H7N9 influenza virus in mice. Chinese Chemical Letters, 2023, 34, 107446.	4.8	2
2	Six-month follow-up of gut microbiota richness in patients with COVID-19. Gut, 2022, 71, 222-225.	6.1	124
3	Characteristics of COVID-19 Patients With SARS-CoV-2 Positivity in Feces. Frontiers in Cellular and Infection Microbiology, 2022, 12, 853212.	1.8	2
4	Akkermansia muciniphila Ameliorates Clostridioides difficile Infection in Mice by Modulating the Intestinal Microbiome and Metabolites. Frontiers in Microbiology, 2022, 13, .	1.5	15
5	Epidemiological and clinical characteristics of 70 cases of coronavirus disease and concomitant hepatitis B virus infection: A multicentre descriptive study. Journal of Viral Hepatitis, 2021, 28, 80-88.	1.0	34
6	Characterization of the Gastric Mucosal Microbiota in Patients with Liver Cirrhosis and Its Associations with Gastrointestinal Symptoms. Engineering, 2021, 7, 507-514.	3.2	0
7	V292I mutation in PB2 polymerase induces increased effects of E627K on influenza H7N9 virus replication in cells. Virus Research, 2021, 291, 198186.	1.1	7
8	Western Diet Aggravated Carbon Tetrachlorideâ€Induced Chronic Liver Injury by Disturbing Gut Microbiota and Bile Acid Metabolism. Molecular Nutrition and Food Research, 2021, 65, e2000811.	1.5	10
9	Alterations in the human oral and gut microbiomes and lipidomics in COVID-19. Gut, 2021, 70, 1253-1265.	6.1	168
10	The faecal metabolome in COVID-19 patients is altered and associated with clinical features and gut microbes. Analytica Chimica Acta, 2021, 1152, 338267.	2.6	60
11	Gut mycobiota alterations in patients with COVID-19 and H1N1 infections and their associations with clinical features. Communications Biology, 2021, 4, 480.	2.0	62
12	Microbiomeâ€"miRNA interactions in the progress from undifferentiated arthritis to rheumatoid arthritis: evidence, hypotheses, and opportunities. Rheumatology International, 2021, 41, 1567-1575.	1.5	3
13	Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension. Frontiers in Cardiovascular Medicine, 2021, 8, 577398.	1.1	3
14	The Salivary Microbiota, Cytokines, and Metabolome in Patients with Ankylosing Spondylitis Are Altered and More Proinflammatory than Those in Healthy Controls. MSystems, 2021, 6, e0117320.	1.7	13
15	C-Reactive Protein Is an Independent Predictor of 30-Day Bacterial Infection Post-Liver Transplantation. Biomolecules, 2021, 11, 1195.	1.8	3
16	Cytokine Signature Associated With Disease Severity in COVID-19. Frontiers in Immunology, 2021, 12, 681516.	2.2	54
17	Lactitol Supplementation Modulates Intestinal Microbiome in Liver Cirrhotic Patients. Frontiers in Medicine, 2021, 8, 762930.	1.2	9
18	Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome. Frontiers in Cellular and Infection Microbiology, 2021, 11, 761192.	1.8	19

#	Article	IF	Citations
19	Characteristics of three microbial colonization states in the duodenum of the cirrhotic patients. Future Microbiology, 2020, 15, 855-868.	1.0	7
20	Recurrence of SARS-CoV-2 nucleic acid positive test in patients with COVID-19: a report of two cases. BMC Pulmonary Medicine, 2020, 20, 308.	0.8	7
21	Translation: Management of Coronavirus Disease 2019 (COVID-19): Experience in Zhejiang Province, China. Infectious Microbes & Diseases, 2020, 2, 55-63.	0.5	16
22	Vital Members in the More Dysbiotic Oropharyngeal Microbiotas in H7N9-Infected Patients. Frontiers in Medicine, 2020, 7, 396.	1.2	6
23	Alterations of the Human Gut Microbiome in Chronic Kidney Disease. Advanced Science, 2020, 7, 2001936.	5.6	82
24	Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19). , 2020, 11, 642.		9
25	Alterations of the Gut Microbiota in Patients With Coronavirus Disease 2019 or H1N1 Influenza. Clinical Infectious Diseases, 2020, 71, 2669-2678.	2.9	557
26	Progress in microencapsulation of probiotics: A review. Comprehensive Reviews in Food Science and Food Safety, 2020, 19, 857-874.	5.9	238
27	Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clinical Infectious Diseases, 2020, 71, 706-712.	2.9	532
28	Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment. Engineering, 2020, 6, 1153-1161.	3.2	202
29	Research progress on human infection with avian influenza H7N9. Frontiers of Medicine, 2020, 14, 8-20.	1.5	28
30	Factors Associated With Prolonged Viral RNA Shedding in Patients with Coronavirus Disease 2019 (COVID-19). Clinical Infectious Diseases, 2020, 71, 799-806.	2.9	395
31	Development and validation of a risk stratification model for screening suspected cases of COVID-19 in China. Aging, 2020, 12, 13882-13894.	1.4	10
32	Gut microbiome analysis as a tool towards targeted non-invasive biomarkers for early hepatocellular carcinoma. Gut, 2019, 68, 1014-1023.	6.1	498
33	Establishment and development of national community-based collaborative innovation demonstration areas to achieve the control target of hepatitis B in China. BMC Infectious Diseases, 2019, 19, 617.	1.3	13
34	Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. Journal of Oral Microbiology, 2019, 11, 1563409.	1.2	93
35	Altered microbiomes distinguish Alzheimerâ€™s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain, Behavior, and Immunity, 2019, 80, 633-643.	2.0	358
36	Interactions Between Gut Microbiota and Hosts and Their Role in Infectious Diseases. Infectious Microbes & Diseases, 2019, 1, 3-9.	0.5	14

#	Article	IF	Citations
37	Benefit of Early Initiation of Neuraminidase Inhibitor Treatment to Hospitalized Patients With Avian Influenza A(H7N9) Virus. Clinical Infectious Diseases, 2018, 66, 1054-1060.	2.9	27
38	Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections. Advanced Healthcare Materials, 2018, 7, 1700509.	3.9	31
39	Disorganized Gut Microbiome Contributed to Liver Cirrhosis Progression: A Meta-Omics-Based Study. Frontiers in Microbiology, 2018, 9, 3166.	1.5	57
40	Epidemiological features of and changes in incidence of infectious diseases in China in the first decade after the SARS outbreak: an observational trend study. Lancet Infectious Diseases, The, 2017, 17, 716-725.	4.6	193
41	The Human Microbiota in Health and Disease. Engineering, 2017, 3, 71-82.	3.2	583
42	Administration of Lactobacillus salivarius LI01 or Pediococcus pentosaceus LI05 prevents CCl4-induced liver cirrhosis by protecting the intestinal barrier in rats. Scientific Reports, 2017, 7, 6927.	1.6	74
43	Long term outcomes in survivors of epidemic Influenza A (H7N9) virus infection. Scientific Reports, 2017, 7, 17275.	1.6	109
44	HuMiChip2 for strain level identification and functional profiling of human microbiomes. Applied Microbiology and Biotechnology, 2017, 101, 423-435.	1.7	16
45	Clostridium difficile colonization and infection in patients with hepatic cirrhosis. Journal of Medical Microbiology, 2017, 66, 1483-1488.	0.7	17
46	Gut microbial profile analysis by MiSeq sequencing of pancreatic carcinoma patients in China. Oncotarget, 2017, 8, 95176-95191.	0.8	160
47	Adjuvant Corticosteroid Treatment in Adults With Influenza A (H7N9) Viral Pneumonia*. Critical Care Medicine, 2016, 44, e318-e328.	0.4	131
48	A new perspective on C-reactive protein in H7N9 infections. International Journal of Infectious Diseases, 2016, 44, 31-36.	1.5	29
49	Prevalence and characteristics of hypoxic hepatitis in the largest single-centre cohort of avian influenza A(H7N9) virus-infected patients with severe liver impairment in the intensive care unit. Emerging Microbes and Infections, 2016, 5, 1-7.	3.0	20
50	Deep sequencing reveals microbiota dysbiosis of tongue coat in patients with liver carcinoma. Scientific Reports, 2016, 6, 33142.	1.6	99
51	Alterations in the Fecal Microbiota of Patients with HIV-1 Infection: An Observational Study in A Chinese Population. Scientific Reports, 2016, 6, 30673.	1.6	153
52	Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. Scientific Reports, 2016, 6, 32002.	1.6	260
53	Dysbiosis of small intestinal microbiota in liver cirrhosis and its association with etiology. Scientific Reports, 2016, 6, 34055.	1.6	165
54	Extracorporeal membrane oxygenation treatment of a H7N9-caused respiratory failure patient with mechanical valves replacement history. Medicine (United States), 2016, 95, e5052.	0.4	7

#	Article	IF	Citations
55	Severe Infection With Avian Influenza A Virus is Associated With Delayed Immune Recovery in Survivors. Medicine (United States), 2016, 95, e2606.	0.4	11
56	Identification of key taxa that favor intestinal colonization of Clostridium difficile in an adult Chinese population. Microbes and Infection, 2016, 18, 30-38.	1.0	73
57	Influence of H7N9 virus infection and associated treatment on human gut microbiota. Scientific Reports, 2015, 5, 14771.	1.6	88
58	Decreased Diversity of the Oral Microbiota of Patients with Hepatitis B Virus-Induced Chronic Liver Disease: A Pilot Project. Scientific Reports, 2015, 5, 17098.	1.6	79
59	Gut dysbiosis in acuteâ€onâ€chronic liver failure and its predictive value for mortality. Journal of Gastroenterology and Hepatology (Australia), 2015, 30, 1429-1437.	1.4	131
60	Biodegradable Antimicrobial Polycarbonates with In Vivo Efficacy against Multidrugâ€Resistant MRSA Systemic Infection. Advanced Healthcare Materials, 2015, 4, 2128-2136.	3.9	50
61	The Therapeutic Effect of Pamidronate on Lethal Avian Influenza A H7N9 Virus Infected Humanized Mice. PLoS ONE, 2015, 10, e0135999.	1.1	12
62	Clostridium butyricumCombined withBifidobacterium infantisProbiotic Mixture Restores Fecal Microbiota and Attenuates Systemic Inflammation in Mice with Antibiotic-Associated Diarrhea. BioMed Research International, 2015, 2015, 1-9.	0.9	44
63	The Serum Profile of Hypercytokinemia Factors Identified in H7N9-Infected Patients can Predict Fatal Outcomes. Scientific Reports, 2015, 5, 10942.	1.6	93
64	Recombinant influenza A virus hemagglutinin HA2 subunit protects mice against influenza A(H7N9) virus infection. Archives of Virology, 2015, 160, 777-786.	0.9	20
65	Re: Gut microbiota depletion from early adolescence in mice: Implications for brain and behavior. Brain, Behavior, and Immunity, 2015, 50, 334.	2.0	1
66	Functional variants regulating LGALS1 (Galectin 1) expression affect human susceptibility to influenza A(H7N9). Scientific Reports, 2015, 5, 8517.	1.6	43
67	Altered fecal microbiota composition in patients with major depressive disorder. Brain, Behavior, and Immunity, 2015, 48, 186-194.	2.0	1,594
68	Who determines the outcomes of HBV exposure?. Trends in Microbiology, 2015, 23, 328-329.	3.5	16
69	Qin et al. reply. Nature, 2015, 525, E2-E3.	13.7	3
70	Alterations of Bacteroides sp., Neisseria sp., Actinomyces sp., and Streptococcus sp. populations in the oropharyngeal microbiome are associated with liver cirrhosis and pneumonia. BMC Infectious Diseases, 2015, 15, 239.	1.3	29
71	Evaluation of Plasma Exchange and Continuous Venoâ€Venous Hemofiltration for the Treatment of Severe Avian Influenza <scp>A</scp> (<scp>H7N9</scp>): A Cohort Study. Therapeutic Apheresis and Dialysis, 2015, 19, 178-184.	0.4	37
72	Avian Influenza A H7N9 Virus Induces Severe Pneumonia in Mice without Prior Adaptation and Responds to a Combination of Zanamivir and COX-2 Inhibitor. PLoS ONE, 2014, 9, e107966.	1.1	35

#	Article	IF	Citations
73	Comparison of a New Gold Immunochromatographic Assay for the Rapid Diagnosis of the Novel Influenza A (H7N9) Virus with Cell Culture and a Real-Time Reverse-Transcription PCR Assay. BioMed Research International, 2014, 2014, 1-6.	0.9	15
74	The K526R substitution in viral protein PB2 enhances the effects of E627K on influenza virus replication. Nature Communications, 2014, 5, 5509.	5.8	155
75	Functional gene arrays-based analysis of fecal microbiomes in patients with liver cirrhosis. BMC Genomics, 2014, 15, 753.	1.2	36
76	Altered Fecal Microbiota Composition Associated with Food Allergy in Infants. Applied and Environmental Microbiology, 2014, 80, 2546-2554.	1.4	295
77	Avian-Origin Influenza A(H7N9) Infection in Influenza A(H7N9)â€"Affected Areas of China: A Serological Study. Journal of Infectious Diseases, 2014, 209, 265-269.	1.9	100
78	Alterations of the human gut microbiome in liver cirrhosis. Nature, 2014, 513, 59-64.	13.7	1,782
79	An analysis of microbiota-targeted therapies in patients with avian influenza virus subtype H7N9 infection. BMC Infectious Diseases, 2014, 14, 359.	1.3	27
80	Immune derangement occurs in patients with H7N9 avian influenza. Critical Care, 2014, 18, R43.	2.5	14
81	Molecular characterization and phylogenetic analysis of H3 subtype avian influenza viruses isolated from domestic ducks in Zhejiang Province in China. Virus Genes, 2014, 49, 80-88.	0.7	14
82	Correlation between reported human infection with avian influenza A H7N9 virus and cyber user awareness: what can we learn from digital epidemiology?. International Journal of Infectious Diseases, 2014, 22, 1-3.	1.5	24
83	Dynamic behavior of lymphocyte subgroups correlates with clinical outcomes in human H7N9 infection. Journal of Infection, 2014, 69, 358-365.	1.7	15
84	Natural killer T cells play a necessary role in modulating of immune-mediated liver injury by gut microbiota. Scientific Reports, 2014, 4, 7259.	1.6	63
85	Severe H7N9 Infection Is Associated with Decreased Antigen-Presenting Capacity of CD14+ Cells. PLoS ONE, 2014, 9, e92823.	1.1	37
86	Infectious Microecology. Advanced Topics in Science and Technology in China, 2014, , 1-22.	0.0	1
87	Dysbiosis Signature of Fecal Microbiota in Colorectal Cancer Patients. Microbial Ecology, 2013, 66, 462-470.	1.4	408
88	Assessment of Microbiome Variation During the Perioperative Period in Liver Transplant Patients: a Retrospective Analysis. Microbial Ecology, 2013, 65, 781-791.	1.4	70
89	The emergence of influenza A H7N9 in human beings 16 years after influenza A H5N1: a tale of two cities. Lancet Infectious Diseases, The, 2013, 13, 809-821.	4.6	129
90	Clinical, Virological, and Histopathological Manifestations of Fatal Human Infections by Avian Influenza A(H7N9) Virus. Clinical Infectious Diseases, 2013, 57, 1449-1457.	2.9	102

#	Article	IF	Citations
91	Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet, The, 2013, 381, 1916-1925.	6.3	781
92	Higher-Level Production of Volatile Fatty Acids In Vitro by Chicken Gut Microbiotas than by Human Gut Microbiotas as Determined by Functional Analyses. Applied and Environmental Microbiology, 2012, 78, 5763-5772.	1.4	53
93	Cationic amphiphilic alpha-helical peptides for the treatment of carbapenem-resistant Acinetobacter baumannii infection. Biomaterials, 2012, 33, 8841-8847.	5.7	31
94	Broad-Spectrum Antimicrobial Supramolecular Assemblies with Distinctive Size and Shape. ACS Nano, 2012, 6, 9191-9199.	7.3	87
95	Metabonomic Profiles Discriminate Hepatocellular Carcinoma from Liver Cirrhosis by Ultraperformance Liquid Chromatographyâ€"Mass Spectrometry. Journal of Proteome Research, 2012, 11, 1217-1227.	1.8	122
96	Changes of Fecal Bifidobacterium Species in Adult Patients with Hepatitis B Virus-Induced Chronic Liver Disease. Microbial Ecology, 2012, 63, 304-313.	1.4	111
97	Biodegradable nanostructures with selective lysis of microbial membranes. Nature Chemistry, 2011, 3, 409-414.	6.6	522
98	Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology, 2011, 54, 562-572.	3.6	883
99	Efficacy of CG₃R₆TAT Nanoparticles Self-Assembled from a Novel Antimicrobial Peptide for the Treatment of <i>Candida albicans </i>Meningitis in Rabbits. Chemotherapy, 2011, 57, 417-425.	0.8	21
100	The efficacy of self-assembled cationic antimicrobial peptide nanoparticles against Cryptococcus neoformans for the treatment of meningitis. Biomaterials, 2010, 31, 2874-2881.	5.7	120
101	Self-assembled cationic peptide nanoparticles as an efficient antimicrobial agent. Nature Nanotechnology, 2009, 4, 457-463.	15.6	583
102	Symbiotic gut microbes modulate human metabolic phenotypes. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2117-2122.	3.3	994